{"id":1884,"date":"2023-03-16T19:02:14","date_gmt":"2023-03-16T18:02:14","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/annualreport\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/"},"modified":"2023-05-23T14:11:16","modified_gmt":"2023-05-23T14:11:16","slug":"ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/","title":{"rendered":"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP"},"content":{"rendered":"<p align=\"left\"><strong>Ipsen obtient une nouvelle <\/strong><strong>PDUFA <\/strong><strong>date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-1884","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP - Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP - Annual Report\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/\" \/>\n<meta property=\"og:site_name\" content=\"Annual Report\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T14:11:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/\",\"name\":\"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP - Annual Report\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\"},\"datePublished\":\"2023-03-16T18:02:14+00:00\",\"dateModified\":\"2023-05-23T14:11:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"name\":\"Annual Report\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\",\"name\":\"Annual Report\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Annual Report\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP - Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP - Annual Report","og_url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/","og_site_name":"Annual Report","article_modified_time":"2023-05-23T14:11:16+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/","url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/","name":"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP - Annual Report","isPartOf":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#website"},"datePublished":"2023-03-16T18:02:14+00:00","dateModified":"2023-05-23T14:11:16+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-obtient-une-nouvelle-pdufa-date-de-la-fda-pour-le-palovarotene-experimental-dans-le-traitement-des-personnes-atteintes-de-fop\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/annualreport\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarot\u00e8ne exp\u00e9rimental dans le traitement des personnes atteintes de FOP"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/annualreport\/#website","url":"https:\/\/www.ipsen.com\/annualreport\/","name":"Annual Report","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/annualreport\/#organization","name":"Annual Report","url":"https:\/\/www.ipsen.com\/annualreport\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg","caption":"Annual Report"},"image":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1884\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/media?parent=1884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/categories?post=1884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/tags?post=1884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}